Avidity Biosciences
Clinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.
About
Technology stack
detected 2026-06-22No comments yet. Be the first to share your take.
What does Avidity Biosciences do?
Avidity Biosciences is developing a new class of targeted RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). These AOCs combine monoclonal antibodies and oligonucleotides to deliver therapies to previously inaccessible tissues and target the underlying genetic drivers of diseases. The company is currently advancing programs for rare muscle diseases including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
How much funding has Avidity Biosciences raised?
Avidity Biosciences has raised a total of $495M in funding. The most recent round on record is IPO.
Where is Avidity Biosciences headquartered?
Avidity Biosciences is headquartered in San Diego, United States.
When was Avidity Biosciences founded?
Avidity Biosciences was founded in 2013.
What industry does Avidity Biosciences operate in?
Avidity Biosciences operates in Biotech, Drug Discovery, Genomics, Clinical Trials, Rare Diseases, Oligonucleotide Therapeutics.
How many employees does Avidity Biosciences have?
Avidity Biosciences has approximately 445 people on record.